Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-372-6 | CAS number: 98730-04-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 1 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 17.5
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 17.5 mg/m³
- Explanation for the modification of the dose descriptor starting point:
- In the absence of a repeated dose toxicity study via the inhalation it is deemed appropriate to use a reliable chronic oral repeated dose toxicity study conducted with dogs.
- AF for dose response relationship:
- 1
- Justification:
- The starting point for the derivation is a chronic NOAEL
- AF for differences in duration of exposure:
- 1
- Justification:
- The starting point for the derivation is a chronic NOAEL
- AF for interspecies differences (allometric scaling):
- 1.4
- Justification:
- This is the assessment factor for allometric scaling from dog to human as given in ECHA guidance R.8, Table R.8-3
- AF for other interspecies differences:
- 2.5
- Justification:
- This is the additional assessment factor for remaining uncertainties due to other interspecies differences
- AF for intraspecies differences:
- 5
- Justification:
- This is the standard assessment factor for intraspecies differences for workers
- AF for the quality of the whole database:
- 1
- Justification:
- No additional assessment factor is applied since the quality of the whole database is considered high
- AF for remaining uncertainties:
- 1
- Justification:
- No additional assessment factor is applied since the quality of the whole database is considered high
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 2.8 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Dermal
DNEL related information
- DNEL derivation method:
- ECHA REACH Guidance
- Overall assessment factor (AF):
- 360
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 1 010 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
- A sub-acute dermal repeated dose toxicity study is available and no route-to-route extrapolation is applied.
- AF for dose response relationship:
- 1
- Justification:
- The starting point for the derivation is a sub-acute NOAEL
- AF for differences in duration of exposure:
- 6
- Justification:
- This is the standard factor for extrapolation from sub-acute to chronic effects
- AF for interspecies differences (allometric scaling):
- 2.4
- Justification:
- This is the assessment factor for allometric scaling from rabbit to human as given in ECHA guidance R.8, Table R.8-3
- AF for other interspecies differences:
- 2.5
- Justification:
- This is the additional assessment factor for remaining uncertainties due to other interspecies differences
- AF for intraspecies differences:
- 5
- Justification:
- This is the standard assessment factor for intraspecies differences for workers
- AF for the quality of the whole database:
- 2
- Justification:
- No additional assessment factor is applied since the quality of the whole database is considered limited
- AF for remaining uncertainties:
- 1
- Justification:
- No additional assessment factor is applied since the quality of the whole database is considered high
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- sensitisation (skin)
Acute/short term exposure
- Hazard assessment conclusion:
- medium hazard (no threshold derived)
- Most sensitive endpoint:
- sensitisation (skin)
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Long-term – dermal, systemic
Identification of relevant endpoints
Relevant long-term dermal data are only available for the endpoint repeat-dose toxicity. In addition, relevant long-term oral data are available for the endpoints repeat-dose and reproduction toxicity.
Available dose-descriptors per endpoint as a result of the hazard assessment |
||||
Endpoint |
Quantitative dose descriptor, system effects |
Associated effects |
Remarks on study |
|
Repeat-dose toxicity |
Oral |
NOAEL: 5 mg/kg bw/day |
Reduced body weight gain; minor disturbance of blood clinical pathology parameters; increases in liver and kidney weights with pigment deposition in the kidney at higher doses |
Dog, oral gavage, 52 weeks |
Oral |
NOEL: 3.3 mg/kg bw/day |
Reduced body weight gain and food consumption; slightly increase liver weights |
Rat, oral dietary, 52 weeks |
|
Derm. |
NOEL: 1010 mg/kg bw/day |
No relevant toxicological effects observed |
Rabbit, dermal-occlusive, 21 days |
|
Inhal. |
No data |
|
|
|
Reproduction toxicity |
Oral |
NOEL: 4 mg/kg bw/day |
No adverse effects on fertility; reduced body weights and food consumption at higher doses |
Rat, oral dietary, fertility |
Derm. |
No data |
|
|
|
Inh. |
No data |
|
|
Repeat-dose Toxicity - rabbit
Dose-descriptor selection
Potential dose-descriptors are available resulting from a 21 day repeat dose dermal study in rabbits.
Assessment of mode of action
The identified endpoint, and the observed effects, have a threshold mode of action.
Dose-descriptor modification
The dose descriptor was modified by the following defaults as laid out in Guidance on Information Requirements and Chemical Safety Assessment, R.8, November 2012.
NOELworker=NOELrabbit*AllometricScaling=1010*1/2.4=421mg/kg
Assessment factors
The default assessment factors were applied as laid out in Guidance on Information Requirements and Chemical Safety Assessment, November 2012, R.8.4.3.3.
Assessment factor = Interspecies * Intraspecies * Exposure Duration * Dose-response * Quality of whole database
AF=inter*intra*duration*DatabaseQuality=2.5*5*6*2=150
DNEL derivation
DNEL = NOAELcorr / Assessment factor
DNEL = 421 mg/kg / 150 = 2.8 mg/kg
Long-term – inhalation, systemic
Identification of relevant endpoints
No relevant long-term inhalation data are available. Relevant long-term oral data are available for the endpoint repeat-dose toxicity and reproduction toxicity.
Available dose-descriptors per endpoint as a result of the hazard assessment |
||||
Endpoint |
Quantitative dose descriptor, system effects |
Associated effects |
Remarks on study |
|
Repeat-dose toxicity |
Oral |
NOAEL: 5 mg/kg bw/day |
Reduced body weight gain; minor disturbance of blood clinical pathology parameters; increases in liver and kidney weights with pigment deposition in the kidney at higher doses |
Dog, oral gavage, 52 weeks |
Oral |
NOEL: 3.3 mg/kg bw/day |
Reduced body weight gain and food consumption; slightly increase liver weights |
Rat, oral dietary, 52 weeks |
|
Derm. |
NOEL: 1010 mg/kg bw/day |
No relevant toxicological effects observed |
Rabbit, dermal-occlusive, 21 days |
|
Inhal. |
No data |
|
|
|
Reproduction toxicity |
Oral |
NOEL: 4 mg/kg bw/day |
No adverse effects on fertility; reduced body weights and food consumption at higher doses |
Rat, oral dietary, fertility |
Derm. |
No data |
|
|
|
Inh. |
No data |
|
|
Repeat-dose Toxicity - rat
Dose-descriptor selection
Potential dose-descriptors are available resulting from a chronic study.
Assessment of mode of action
The identified endpoint, and the observed effects, have a threshold mode of action.
Dose-descriptor modification
The dose descriptor was modified by the following defaults as laid out in Guidance on Information Requirements and Chemical Safety Assessment, November 2012, R.8.4.2: extrapolation from the oral-to-inhalation route, light-work respiratory volume in the worker, 50% oral absorption, 100% inhalation absorption, assumed no first-pass effect.
NOAELcorr = NOAEL*1/rat respiratory volume*human/worker respiratory volume*Oral absorption/Inhalation absorption
NOAELcorr (worker) = 3.3 mg/kg*1/0.38m3/kg*6.7m3/10m3*1/2 = 2.9 mg/m3
Assessment factors
The default assessment factors were applied as laid out in Guidance on Information Requirements and Chemical Safety Assessment, November 2012, R.8.4.3.3. While an additional assessment factor could be applied for use of repeat-dose toxicity data to meet a reproductive toxicity endpoint (Appendix R.8-12), this endpoint only addresses repeat-dose toxicity and as such a further factor is not warrant. Allometric scaling has been accounted for in the dose-descriptor modification.
Assessment factor = Interspecies * Intraspecies * Exposure Duration * Dose-response * Quality of whole database
Assessment factor (worker) = 2.5 * 5 * 1 * 1 * 1 = 12.5
DNEL derivation
DNEL = NOAELcorr / Assessment factor
DNEL = 2.9 mg/m3/ 12.5 = 0.23 mg/m3
Repeat-dose Toxicity - dog
Dose-descriptor selection
Potential dose-descriptors are available resulting from a chronic study.
Assessment of mode of action
The identified endpoint, and the observed effects, have a threshold mode of action.
Dose-descriptor modification
The dose descriptor was modified by the following defaults as laid out in Guidance on Information Requirements and Chemical Safety Assessment, November 2012, R.8.4.2 (and following example R.8-2 workers): extrapolation from the oral-to-inhalation route, light-work respiratory volume in the worker, 50% oral absorption, 100% inhalation absorption, assumed no first-pass effect.
NOAELcorr = NOAEL*1/allometric scaling*bodyweight/worker respiratory volume*Oral absorption/Inhalation absorption
NOAELcorr (worker) = 5 mg/kg*1/1.4/kg*70kg/10 m3/2 = 12.5 mg/m3
Assessment factors
The default assessment factors were applied as laid out in Guidance on Information Requirements and Chemical Safety Assessment, November 2012, R.8.4.3.3. While an additional assessment factor could be applied for use of repeat-dose toxicity data to meet a reproductive toxicity endpoint (Appendix R.8-12), this endpoint only addresses repeat-dose toxicity and as such a further factor is not warrant. Allometric scaling has been accounted for in the dose-descriptor modification.
Assessment factor = Interspecies * Intraspecies * Exposure Duration * Dose-response * Quality of whole database
Assessment factor (worker) = 2.5 * 5 * 1 * 1 * 1 = 12.5
DNEL derivation
DNEL = NOAELcorr / Assessment factor
DNEL = 12.5 mg/m3/ 12.5 = 1 mg/m3
Looking at the NOAELs not in isolation, there is a 10-fold difference between the NOAEL and the LOAEL in rat chronic study, and the dog NOAEL fits within this range. The toxicity profiles are comparable, and the dog NOAEL was used for the DNEL derivation. As a result, the worker long-term inhalation DNEL for systemic effects is 1 mg/cubic metre based on the dog study.
Long-term – dermal, local
Identification of relevant endpoints
Relevant long-term dermal-route data for local effects are available.
Available dose-descriptors per endpoint as a result of the hazard assessment |
||||
Endpoint |
Qualitative dose descriptor, systemic effects |
Associated effects |
Remarks on study |
|
Skin sensitisation |
Dermal |
Sensitising, “moderate hazard” |
Sensitisation observed |
Variant on the Buehler test. All 10 treated guinea pigs showed positive skin reactions to the test material after challenge on day 36. |
Skin Sensitisation
1. Dose-descriptor selection
A single study is available which gives information on skin sensitisation potential. The test substance was found to be sensitising on the basis of an EPAOPP 81-6 (similar to the occluded Buehler test). The substance was classified based on the clearly positive result.
2. Assessment of mode of action
The identified endpoint, and the observed effects, have a threshold mode of action. However, no quantitative dose-response information for this endpoint is available and as such no DNEL can be derived. As a result, a qualitative risk assessment is required.
3. Semi-quantitative risk assessment
The application concentration of the test material during induction phase was 0.5 g in 0.5 mL of water, equating to ca. 50wt%. It should be noted the water solubility is 38 mg/L at 25 °C.
On the basis of ECETOC Technical Report No. 87, Contact Sensitisation: Classification According to Potency, April 2003, 2.2.1, Table 5, the test substance could be categorised as a “weak sensitiser”, using the 50wt% concentration used in topical administration during induction, and the subsequent 100% elicitation incidence in the 50wt% challenge.
However, the recommendations in the ECHA Guidance, Chapter R.8, November 2012, Appendix R.8-10, Table R.8-25, based on the EU Working Group on Skin Sensitisation, suggest that with an induction concentration of >20%, and >=60% observed sensitisation, the potency is “moderate” with a high degree of uncertainty.
As a result, a qualitative risk assessment approach based on the “moderate sensitiser” potency categorisation is undertaken.The potency categorisation of the test substance, in combination with the Hazard Categories given in the Guidance, Part E: Risk Characterisation, November 2012, Table E.3-1, results in a “moderate hazard” categorisation for the purposes of risk assessment. This categorisation is carried forward to Risk Characterisation.
Selection of leading health effect and DNEL
Information relevant to long-term dermal, local effects, is available from one endpoint – skin sensitization. The result of the qualitative assessment of potency “moderate hazard” is taken forward to Risk Characterisation.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
The substance is, during its whole life-cycle, used only by workers/professionals, thus never by consumers. The assessment of indirect exposure of humans via the environment is not considered to be required for this substance (based on tonnage band and classification, see Guidance on Information Requirements and Chemical Safety Assessment, October 2012, R.16.6.8.3). As a consequence the derivation of DNELs for the general population is not required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
